A single infusion of allogeneic Vγ9Vδ2 T-cells, expanded ex vivo with ZOL plus IL-2, is being administered in a clinical trial (NCT03533816) to maximize antitumor response and reduce GvHD, after allogeneic hematopoietic cell transplant (alloHCT) and cyclophosphamide for hematologic malignancies. This evidence concerns the gene IL2 and hematologic disorder.